Stryker Corporation 8-K
PositiveEarningsCybersecurity incidentGuidance
Higher unit volume drove MedSurg/Neurotechnology and Orthopaedics growth; cyber recovery progressed and FY2026 guidance narrowed.
Filed 2026-07-30 16:09 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q2 2026 results with narrowed FY2026 guidance. Sales, earnings and operating cash flow grew as Stryker reported progress recovering from the cyber incident. Growth was driven by higher unit volume.
Key Figures
| Metric | Q2 2026 | Q2 2025 | Y/Y |
|---|---|---|---|
| Net sales | $6.59B | $6.02B | 9.4% |
| Operating income | $1.66B | $1.11B | 49.1% |
| Net earnings | $1.28B | $884M | 44.3% |
| Adjusted net earnings, non-GAAP | $1.42B | $1.21B | 17.6% |
| Diluted EPS | $3.30 | $2.29 | 44.1% |
| Adjusted diluted EPS, non-GAAP | $3.69 | $3.13 | 17.9% |
- Organic net sales growth was 9.0%; MedSurg and Neurotechnology sales rose 9.2% organically and Orthopaedics sales rose 8.6%, primarily on higher unit volume.
- Operating income margin was 25.2%, up from 18.5%; adjusted operating income margin was 27.4%, up 170 bp.
- H1 operating cash flow was $1.84B vs $1.36B, alongside net earnings of $2.02B vs $1.54B. Cash was $3.39B at 6/30/2026 vs $4.01B at 12/31/2025; long-term debt excluding current maturities was $14.2B vs $14.9B.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Organic net sales growth | FY2026 | 8.3%-9.3% | — | narrowed |
| Adjusted net earnings per diluted share, non-GAAP | FY2026 | $14.95-$15.10 | — | narrowed |
Sales guidance includes a modestly positive pricing impact; foreign exchange is expected to be slightly favorable for sales and adjusted EPS if rates remain near current levels.
Investor Takeaways
- FY2026 organic sales growth and adjusted EPS versus the narrowed ranges will show whether the Q2 momentum carries through the second half.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3